Eleven Biotherapeutics Inc. (EBIO) 10.13 $EBIO
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 30, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BAMM: 2.57 (+0.01), EBIO: 10.13 (+0.05), UBSI: 36.83 (-0.01), GTWN: 17.55 (-0.40), GURE: 1.64 (-0.04), HTWO: 10.20 (-0.30)
Eleven Biotherapeutics to Present in Upcoming Investor Conferences in February
Business Wire - Thu Jan 29, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences in February:
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors
Business Wire - Thu Jan 22, 7:01AM CST
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Barry Gertz, MD, PhD, and Jay S. Duker, MD, to the company's Board of Directors. Each of these new Board members brings more than 25 years of experience that is relevant to Eleven's progress in advancing its pipeline of innovative therapies for ocular diseases.
EBIO: 10.13 (+0.05), MRK: 58.81 (-0.07)
Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Nov 26, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 10:55 a.m. ET.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics expects USD20m from private placement
M2 - Wed Nov 26, 6:44AM CST
Biopharmaceutical company Eleven Biotherapeutics (NasdaqGM:EBIO) disclosed on Tuesday the planned sale of USD20m of its common stock and warrants to a select group of investors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Business Wire - Tue Nov 25, 7:05AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has entered into a securities purchase agreement for the sale of $20 million of Eleven Biotherapeutics common stock and warrants in a private placement financing with a select group of investors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics revenues down 17% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 12:13PM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics' (EBIO) CEO Abbie Celniker on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:51AM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics misses by $0.22, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:44AM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 13, 6:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014
Business Wire - Tue Nov 04, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2014 financial results on Thursday, November 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. EST, on Thursday, November 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease
Business Wire - Mon Nov 03, 7:30AM CST
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven's lead drug candidate in development for the treatment of moderate to severe dry eye disease and allergic conjunctivitis.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors
Business Wire - Thu Oct 23, 7:30AM CDT
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the appointment of industry veteran Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005
Business Wire - Tue Oct 07, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the issuance of U.S. Patent No. 8,853,150 entitled "Chimeric Il-1 Receptor Type I Agonists and Antagonists." This patent covers the composition-of-matter of Eleven's lead product candidate, EBI-005, a topically-administered interleukin-1 (IL-1) receptor blocker, certain other compositions that are IL-1 receptor antagonists, and related methods for treating ocular surface inflammatory diseases, such as dry eye disease and allergic conjunctivitis. Designed, engineered and generated using Eleven's AMP-Rx platform, EBI-005 is being developed as a topical protein therapeutic for ocular diseases. Eleven recently reported top-line results of a Phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis and is currently evaluating EBI-005 in a pivotal Phase 3 clinical study in patients with dry eye disease, with top-line data expected in early 2015.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis
Business Wire - Thu Oct 02, 5:00AM CDT
--- Study Does Not Meet Primary Endpoint Using Environmental Exposure Chamber Model -
EBIO: 10.13 (+0.05)
How Eleven Biotherapeutics (EBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:51AM CDT
Eleven Biotherapeutics might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September
Business Wire - Thu Aug 28, 3:01PM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences in September:
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Fri Aug 01, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report second quarter 2014 financial results on Wednesday, August 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Wednesday, August 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 10.13 (+0.05)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 30, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BAMM: 2.57 (+0.01), EBIO: 10.13 (+0.05), UBSI: 36.83 (-0.01), GTWN: 17.55 (-0.40), GURE: 1.64 (-0.04), HTWO: 10.20 (-0.30)
Eleven Biotherapeutics to Present in Upcoming Investor Conferences in February
Business Wire - Thu Jan 29, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences in February:
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors
Business Wire - Thu Jan 22, 7:01AM CST
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Barry Gertz, MD, PhD, and Jay S. Duker, MD, to the company's Board of Directors. Each of these new Board members brings more than 25 years of experience that is relevant to Eleven's progress in advancing its pipeline of innovative therapies for ocular diseases.
EBIO: 10.13 (+0.05), MRK: 58.81 (-0.07)
Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Nov 26, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 10:55 a.m. ET.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics expects USD20m from private placement
M2 - Wed Nov 26, 6:44AM CST
Biopharmaceutical company Eleven Biotherapeutics (NasdaqGM:EBIO) disclosed on Tuesday the planned sale of USD20m of its common stock and warrants to a select group of investors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Business Wire - Tue Nov 25, 7:05AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has entered into a securities purchase agreement for the sale of $20 million of Eleven Biotherapeutics common stock and warrants in a private placement financing with a select group of investors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics revenues down 17% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 12:13PM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics' (EBIO) CEO Abbie Celniker on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:51AM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics misses by $0.22, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:44AM CST
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 13, 6:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014
Business Wire - Tue Nov 04, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2014 financial results on Thursday, November 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. EST, on Thursday, November 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease
Business Wire - Mon Nov 03, 7:30AM CST
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven's lead drug candidate in development for the treatment of moderate to severe dry eye disease and allergic conjunctivitis.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors
Business Wire - Thu Oct 23, 7:30AM CDT
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the appointment of industry veteran Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005
Business Wire - Tue Oct 07, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the issuance of U.S. Patent No. 8,853,150 entitled "Chimeric Il-1 Receptor Type I Agonists and Antagonists." This patent covers the composition-of-matter of Eleven's lead product candidate, EBI-005, a topically-administered interleukin-1 (IL-1) receptor blocker, certain other compositions that are IL-1 receptor antagonists, and related methods for treating ocular surface inflammatory diseases, such as dry eye disease and allergic conjunctivitis. Designed, engineered and generated using Eleven's AMP-Rx platform, EBI-005 is being developed as a topical protein therapeutic for ocular diseases. Eleven recently reported top-line results of a Phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis and is currently evaluating EBI-005 in a pivotal Phase 3 clinical study in patients with dry eye disease, with top-line data expected in early 2015.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis
Business Wire - Thu Oct 02, 5:00AM CDT
--- Study Does Not Meet Primary Endpoint Using Environmental Exposure Chamber Model -
EBIO: 10.13 (+0.05)
How Eleven Biotherapeutics (EBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:51AM CDT
Eleven Biotherapeutics might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September
Business Wire - Thu Aug 28, 3:01PM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences in September:
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.
EBIO: 10.13 (+0.05)
Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Fri Aug 01, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report second quarter 2014 financial results on Wednesday, August 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Wednesday, August 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 10.13 (+0.05)
